GS-9256
- Generic Name
- GS-9256
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C46H56ClF2N6O8PS
- CAS Number
- 1001094-46-7
- Unique Ingredient Identifier
- 8V42Y78HRU
- Background
GS-9256 has been used in trials studying the treatment of HCV Infection and Chronic Hepatitis C Infection.
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-10-21
- Last Posted Date
- 2014-01-28
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 324
- Registration Number
- NCT01225380
- Locations
- 🇺🇸
UT Southwestern Medical Center at Dallas, Dallas, Texas, United States
🇨🇦Toronto General Hospital, Toronto, Ontario, Canada
🇺🇸Medical Associates Research Group, San Diego, California, United States
Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus Infection
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-02-22
- Last Posted Date
- 2012-05-31
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 46
- Registration Number
- NCT01072695
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath